论文部分内容阅读
目的探讨吉西他滨联合顺铂(GP方案)及紫杉醇联合顺铂(TP方案)治疗老年晚期非小细胞肺癌的临床疗效。方法将88例老年晚期非小细胞肺癌患者随机分为GP组(42例)与TP组(46例),分别接受吉西他滨及紫杉醇联合顺铂治疗,化疗2个周期后评估客观有效率(ORR)、1年生存率、中位生存时间和不良反应。结果 GP组和TP组患者的ORR分别为38.1%和37.0%,差异无统计学意义(P>0.05);GP组患者的中位生存时间为8.7个月,1年生存率为33.3%,与TP组比较差异无统计学意义(8.8个月和32.6%,P>0.05)。与TP组相比,GP组患者的Ⅲ~Ⅳ白细胞减少发生率显著降低,而血小板减少发生率显著升高(P<0.05)。结论吉西他滨、紫杉醇联合顺铂治疗老年晚期非小细胞肺癌近期临床疗效相当,不良反应可耐受。
Objective To investigate the clinical efficacy of gemcitabine combined with cisplatin (GP) and paclitaxel plus cisplatin (TP) in the treatment of elderly patients with advanced non-small cell lung cancer. Methods Eighty-nine elderly patients with advanced non-small cell lung cancer were randomly divided into GP group (42 cases) and TP group (46 cases). They were treated with gemcitabine and paclitaxel combined with cisplatin, and the objective response rate (ORR) was evaluated after 2 cycles of chemotherapy. , 1-year survival rate, median survival time and adverse reactions. Results The ORRs of GP and TP patients were 38.1% and 37.0%, respectively, with no statistically significant difference (P>0.05). The median survival time of GP patients was 8.7 months, and the 1-year survival rate was 33.3%. There was no significant difference in TP group (8.8 months and 32.6%, P>0.05). Compared with the TP group, the incidence of III-IV leukocytopenia was significantly lower in the GP group, and the incidence of thrombocytopenia was significantly higher (P<0.05). Conclusion Gemcitabine, paclitaxel combined with cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer in the short-term clinical efficacy, adverse reactions can be tolerated.